Mark B. Geyer, MD
Leukemia Specialist & Cellular Therapist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Adult Acute and Chronic Leukemias
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Lymphocytic Leukemia (CLL)
About Me
- Adolescent and Young Adult Program Leader, Leukemia Service
- Adult Lymphoblastic Leukemia Program Leader, Leukemia Service
- Chair, Quality Assessment, Cellular Therapy Service
I am a hematologist and medical oncologist who specializes in caring for people with leukemia. I am a member of the Leukemia Service and Cellular Therapy Service at Memorial Sloan Kettering Cancer Center (MSK). I am committed to providing personalized, compassionate care for our patients and their families.
Read more
I often meet patients and their families and caregivers during a very challenging and emotionally charged period in their lives. I value the strong partnerships that our clinical team forms with our patients and their caregivers through both illness and wellness. I want us to make important decisions about care together.
Caring for and adolescent and young adult (AYA) patients with leukemia is particularly important to me. At the time of their diagnosis, many AYAs with leukemia are continuing education or training, starting their careers, and building relationships and families. In my role as AYA Program Leader for the Leukemia Service, I work with other providers in the Lisa and Scott Stuart Center for Adolescent and Young Adult Cancers to meet the unique medical, social, and emotional needs of our AYA patients and their families. These efforts include ensuring our AYA patients have access to well-designed clinical trials run by both the Pediatric and Adult Leukemia Services.
As a researcher, I want to improve the way we treat blood cancers. My research focuses on learning about and developing safe and effective therapies for acute lymphoblastic leukemia and other blood cancers. I have a strong interest, for example, in using the power of the immune system to fight blood cancers more effectively. This treatment approach is called immunotherapy. I am able to prescribe commercially available chimeric antigen receptor (CAR) T cell therapies for people with leukemia or lymphoma. I am also leading several clinical trials investigating new CAR T cell therapies and ways to make these treatments safer and more effective. CAR T cell therapy has a different set of challenges compared with traditional chemotherapy. Because of the skill and experience of the nurses and doctors at MSK, we can deliver the newest treatments in the safest possible manner.
When I meet with patients, my goal is for them to leave the appointment feeling informed and empowered. I want them to know that they are in good hands. I listen carefully to their perspective and address their concerns. I also explain the range of options available to us, outline the advantages and disadvantages of each, and offer my recommendations. I often remind my patients and their families that we never stop caring for them. Our entire team of experts will be there to support and guide them through all the stages of their journey.
Outside of MSK, I enjoy staying active, including distance running, listening to live music, including local artists, discovering new places in New York City and around the world, and spending time with my fiancé. It is always wonderful to learn how my patients like to spend their time as well, so our team can support them as best as possible.
A leukemia specialist is a doctor with special training in diagnosing and treating leukemia.
A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.
My Specialties
- Adult Acute and Chronic Leukemias
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Lymphocytic Leukemia (CLL)
- Chronic Myeloid Leukemia (CML)
- Hairy Cell Leukemia
- Lymphoproliferative Disorders
- Cellular Immunotherapy
Education
- MD, Columbia University College of Physicians and Surgeons
Residencies
- Internal Medicine – Massachusetts General Hospital
Awards and Honors
- Memorial Sloan Kettering Department of Medicine Teaching Excellence Award (2021-2022)
- Memorial Sloan Kettering Hematology Attending Teaching Award (2020-2021)
- American Society of Hematology Scholar Award (2018-2020)
- Lymphoma Research Foundation Postdoctoral Fellowship Grant (2017-2019)
- Abstract Achievement Award, American Society of Hematology (2016)
- Conquer Cancer Foundation Merit Award, American Society of Clinical Oncology (2016)
Fellowships
- Hematology/Medical Oncology – Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Hematology
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Geyer sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Geyer
- A Phase 1 Study of CD371-Targeting CAR T Cell Therapy in People With Acute Myeloid Leukemia
- A Phase 1 Study of DZD8586 in People With B-Cell Non-Hodgkin Lymphoma
- A Phase IB Study of Mosunetuzumab in People with Recurrent or Persistent Chronic Lymphocytic Leukemia
- A Pilot Study of 131-I Apamistamab and CAR T-Cell Therapy in People with Recurrent or Persistent Leukemia or Lymphoma
Read more
- Clinical Trials Co-Investigated by Dr. Geyer
- A Phase 1 Study of 19-28z/IL-18 CAR T Cell Therapy in People With Acute Lymphoblastic Leukemia
- A Phase 1 Study of ADCLEC.syn1 CAR T Cell Therapy in People With Acute Myeloid Leukemia
- A Phase 1 Study of CB-012 CAR T Cell Therapy in People With Acute Myeloid Leukemia
- A Phase 2 Study of Vemurafenib and Obinutuzumab Versus Cladribine and Rituximab in People With Untreated Hairy Cell Leukemia
- A Phase I Study of UCART22 CAR T-Cell Therapy in Children and Young Adults with Recurrent or Persistent B-Cell Acute Lymphoblastic Leukemia
- A Phase II/III Study of Calaspargase Pegol for Adults with Newly Diagnosed Philadelphia-negative Acute Lymphoblastic Leukemia
- A Study Assessing Minimal Residual Disease to Minimize Side Effects in People with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Treated with Venetoclax
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Geyer MB, Shaffer BC, Bhatnagar B, Mims AS, Klein V, Dilip D, Glass JL, Lozanski G, Hassoun H, Landau H, Zhang Y, Xiao W, Roshal M, Park JH. 2023. Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal. Blood Advances. 7: 3087-3098.
Geyer MB, Ritchie EK, Rao AV, Vemuri S, Flynn J, Hsu M, Devlin SM, Roshal M, Gao Q, Shukla M, Salcedo J, Maslak P, Tallman MS, Douer D, Park JH. 2021. Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica. 106: 2086-2094.
Read more
Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Halton E, van Leeuwen DG, Sadelain M, Palomba ML, Park JH, Brentjens RJ. 2019. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T-cells for relapsed/refractory CLL. JCI Insight. 4(9): e122627.
King AC, Pappacena JJ, Tallman MS, Park JH, Geyer MB. 2019. Blinatumomab Administered Concurrently with Oral Tyrosine Kinase Inhibitor Therapy is a Well-Tolerated Consolidation Strategy and Eradicates Measurable Residual Disease in Adults with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Leukemia Research. 79: 27-33.
Visit PubMed for a full listing of Dr. Geyer’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Mark B. Geyer discloses the following relationships and financial interests:
-
Jazz Pharmaceuticals
Professional Services and Activities -
Sanofi-Aventis U.S. LLC
Professional Services and Activities
-
Takeda Pharmaceuticals
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].